KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Preferred Stock Liabilities: 2018-2019

  • Castle Biosciences' Preferred Stock Liabilities was N/A to $45.1 million in Q2 2019 from the same period last year, while for Jun 2019 it was $45.1 million, marking a year-over-year change of. This contributed to the annual value of $45.0 million for FY2018, which is N/A change from last year.
  • Castle Biosciences' Preferred Stock Liabilities amounted to $45.1 million in Q2 2019, which was up 0.25% from $45.0 million recorded in Q4 2018.
  • In the past 5 years, Castle Biosciences' Preferred Stock Liabilities ranged from a high of $45.1 million in Q2 2019 and a low of $45.0 million during Q4 2018.
  • For the 2-year period, Castle Biosciences' Preferred Stock Liabilities averaged around $45.1 million, with its median value being $45.1 million (2018).